Press Releases

Press Releasesp10

December 12, 2015: KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing (Download PDF)

December 1, 2015: KAHR obtains regulatory approval to start a Phase-I/IIa clinical trial with KAHR-102 in lymphoma patients. Trial to start in Israel in mid 2016. (Download PDF, Hebrew)

October 13, 2015: KAHR obtains final reports of toxicology studies for KAHR-102. Studies show KAHR-102 is well tolerated in mice and monkeys. (Download PDF, Hebrew)

December 16, 2014: KAHR Medical receives government grant sum of 8.2 M Shekels approved by the Chief Scientist Office (Download PDF)

February 4, 2013: KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101.(Download PDF)

June 26, 2012: KAHR Medical and Cobra Biologics extend their partnership to develop both KAHR-101 and KAHR-102 (Download PDF)

June 25, 2012: KAHR Medical raise $2.6M (Download PDF)

June 15, 2011: RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102
(Download PDF)

April 14, 2011: Sanofi-Aventis and Hadasit Bio-Holdings invest in KAHR Medical (Download PDF)

December, 2009: KAHR Medical raises 1.5 million sheqels from Hadasit Bio-Holdings and moves towards a clinical trial of immune-system diseases and cancer (Download PDFDownload PDF - Hebrew)
 
May 11, 2009: KAHR Medical and Cobra Partner to Develop
Trans Signal Converter Protein Production (Download PDF)
 
February 19, 2009: KAHR Medical, a Hadasit Bio-holdings Portfolio Company, Announces Scientific Advisory Board
(Download PDF)
 
January 28, 2009: KAHR Medical Raises $500K from Hadasit Bio-Holdings and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel (Download PDF)